Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Corey Anderson

Family Medicine Mesa, AZ Medical Doctor

NPI 1720050727 CMS profile 259762

1840 S Stapley Dr, Mesa, AZ 85204

Open in the dashboard

General payments

$8,138

49 records reported · program years 2019–2024

Research payments

$138,055

Paid to them · 44 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$21,477,144 paid to institutions, not to them · program years 2019–2025

Through program year 2024, Corey Anderson of Mesa, AZ is reported in the CMS Open Payments database as having received $8,138 across 49 general payments and $138,055 in research payments paid to them. Separately, studies naming them as principal investigator received $21,477,144 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $1,933 9
2024 Research $3,929 25
2023 General $2,018 18
2023 Research $5,168 3
2022 General $2,204 6
2022 Research $125,840 8
2021 General $46 3
2021 Research $2,401 6
2020 General $688 8
2020 Research $717 2
2019 General $1,250 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Corey Anderson
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Corey Anderson were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Corey Anderson Family Medicine median Middle half National median
2019 $1,250 $150 $41–$543 $163
2020 $688 $120 $32–$415 $114
2021 $46 $137 $35–$551 $132
2022 $2,204 $137 $37–$512 $149
2023 $2,018 $149 $42–$545 $160
2024 $1,933 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Alnylam Pharmaceuticals Inc. $3,594 21 payments
  2. Boehringer Ingelheim International GmbH $1,336 11 payments
  3. Pfizer Inc. $1,270 6 payments
  4. Merck Sharp & Dohme Corporation $1,225 1 payment
  5. Shionogi Inc $688 8 payments
  6. Abbott Laboratories $26 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Travel and Lodging $5,160 20 payments
  2. Food and Beverage $1,733 27 payments
  3. Consulting Fee $1,225 1 payment
  4. Gift $20 1 payment
Products named General payments · program years 2019–2024
  1. Proclaim IPG $26 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Valneva Austria GmbH $125,067 6 payments
  2. Pfizer Inc. $4,613 2 payments
  3. Eli Lilly and Company $4,446 11 payments
  4. Sanofi Pasteur Inc. $3,929 25 payments

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

281

Median for Family Practice: 1,826

Drug cost

$894

Median for Family Practice: $120,094

Branded share of claims

31.7%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 31 $277
Azithromycin Generic 65 $153
Cephalexin Generic 25 $120
Prednisone Generic 75 $115
Tizanidine Hcl Generic 27 $93
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 14 $58
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 20 $39
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 24 $39

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$2,211

Medicare's payments for the services billed

Medicare patients

33

Average age 72

Services billed

43

21 women, 12 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

93 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record